The Record Should Explain the Decision

Weak decision records create business exposure

This is not a theoretical documentation issue. FDA completed 1,309 drug-quality inspections or recognized partner inspections in FY2025; 60% were classified voluntary action indicated and 18% official action indicated. ¹

In the same fiscal year, FDA’s electronically generated inspection data included 713 drug Form FDA 483s, with quality-unit procedure failures cited 243 times and inadequate investigations cited 164 times.²

The executive concern is larger than inspection preparation. In FDA’s review of nearly 10,000 original applications and supplements requiring facility assessment, 28% received a Complete Response Letter; 43% of those letters—12% of all submissions reviewed—were associated with facility withholds. FDA identified inadequate investigations and insufficient documentation of quality-unit decisions among the common inspection citations connected to those withholds.¹

A weak decision record can therefore become a regulatory, operational, and growth constraint. The organization may have made the right decision and still be poorly positioned to demonstrate it when product release, inspection response, application approval, supply continuity, or executive confidence depends on the answer.

Scattered evidence creates a second obligation

Consider a batch released after a deviation. The investigation is complete, results meet specification, and the authorized person approves disposition. Six months later, a reviewer asks a harder question:

Why was release justified despite the uncertainty that existed at the time?

The answer may be sound. But if it is distributed across the deviation, risk assessment, batch history, technical attachments, meeting notes, email, and the memories of the original team, the company has created a second obligation: reconstruct the decision before it can defend it.

That reconstruction consumes scarce senior capacity at exactly the wrong time. Quality leaders are pulled from current operations; technical experts must rediscover context; Regulatory and Legal may need to reconcile inconsistent accounts; and executives must decide whether the record supports the company’s position or requires broader corrective action.

The vulnerability is not simply missing paperwork. It is the absence of a reliable connection between the evidence available then and the authorization made then.

Signatures do not explain why proceeding was reasonable

An approval signature proves that an authorized action occurred. It does not necessarily show:

• Which evidence materially supported the conclusion.
• Which facts challenged it.
• What assumptions or uncertainty remained.
• Which alternatives were available.
• Why the selected course was proportionate.
• Who accepted the residual risk.
• What conditions or follow-up made the decision acceptable.

The same gap appears in CAPA closure. A file may contain implementation evidence, an effectiveness check, a closure date, and an approver, yet still leave unanswered why the observation period was sufficient, whether the original failure mode had a realistic chance to recur, and why the available evidence supported closure.

FDA’s requirements make the distinction consequential. Before a batch is released or distributed, production and control records must be reviewed and approved by the quality unit; unexplained discrepancies and specification failures must be thoroughly investigated, and the written investigation record must include conclusions and follow-up. FDA’s OOS guidance likewise says an investigation should be thorough, timely, unbiased, well documented, and scientifically sound.^{3, 4}

The signature is necessary. The decision explanation is what enables the signature to withstand scrutiny.

Reconstruction consumes senior capacity and slows operations

Inspection disruption: Preserve the rationale before scrutiny

When a reviewer cannot follow the decision from the record, the inspection burden expands. The organization must search across systems, retrieve communications, schedule subject-matter experts, reconcile competing recollections, and prepare an explanation under external pressure.

This is not an argument for predicting every inspector question. It is an argument for preserving the company’s own reasoning before the organization loses the people and context needed to explain it.

Operational delay: Make prior judgments usable

An unclear prior decision slows the next one. Teams hesitate to close a related CAPA, disposition another batch, approve a change, or respond to a recurring signal because they cannot quickly establish what the earlier team concluded and on what basis.

A decision record reduces that friction. It gives the next reviewer a usable starting point rather than an archive-search assignment.

Management exposure: Show how authority was exercised

Quality-unit authority is explicit: the unit is responsible for approving or rejecting materials and drug products and for ensuring errors are fully investigated. ICH Q10 also places pharmaceutical-quality-system governance with senior management and calls for effective escalation, defined authority, management review, and appropriate resources.^{5, 6}

When the rationale for a consequential decision cannot be retrieved, the problem can rise above document quality. It can become a question of whether management oversight, quality authority, and risk acceptance operated as intended.

Approval and supply risk: Keep record gaps from spreading

FDA’s FY2025 analysis connected facility-withhold risk to pre-existing compliance status and highlighted inadequate investigations and insufficient documentation of quality-unit decisions among relevant inspection citations. The practical consequence is that a record weakness can travel: from one event, to an inspection finding, to remediation commitments, to delayed approvals or supply decisions.¹

Not every documentation gap produces that outcome. But the potential cost is high enough that consequential decisions deserve a stronger standard than “the required fields were completed.”

Seven elements make a consequential decision portable

The solution is not a longer investigation template. It is a concise authorization record that explains the decision.

For each consequential decision, preserve seven elements in one retrievable place:

1. Decision and authority — State exactly what was authorized, by whom, and within what authority.
2. Controlling evidence — Identify the few records and findings that materially supported the conclusion; do not make the next reviewer infer their significance from an attachment list.
3. Contrary evidence — Preserve findings, limitations, and unresolved questions that challenged the selected course.
4. Alternatives considered — Record the realistic options, such as release, hold, additional investigation, testing, rework, rejection, extension, escalation, or recall assessment.
5. Residual risk — State what remained uncertain and why that uncertainty was accepted, controlled, transferred, or escalated.
6. Decision rationale — Connect the evidence to the authorization in plain, reviewable language.
7. Conditions and follow-up — Define interim controls, monitoring, owners, deadlines, effectiveness checks, and triggers that would reopen the decision.

The level of formality should match the risk. ICH Q9(R1) states that effort, formality, and documentation should be commensurate with risk, and it warns that subjectivity can affect risk identification, scoring, and decisions unless bias, assumptions, data, and relevant knowledge are addressed. A routine event does not need an essay; a decision with meaningful patient, product, regulatory, or supply consequences needs enough reasoning to stand without the original meeting participants.⁷

Test one completed decision in 30 minutes

Select one completed decision from the last six months and give the permanent record to a qualified reviewer who was not involved. Do not provide an oral briefing.

Ask the reviewer to answer:

If the reviewer must search private inboxes, interview the original team, or infer the rationale from disconnected attachments, the decision is not yet portable. The company remains dependent on people to supply meaning that the permanent record does not contain.

Start with the decisions carrying the greatest exposure

Do not launch an enterprise documentation program. Start with the decision types that carry the greatest combination of uncertainty, consequence, and future scrutiny:

• Batch release or disposition after a meaningful deviation.
• CAPA closure where recurrence evidence is limited or the observation period is debatable.
• OOS invalidation or release after an atypical result.
• Continued operation under interim controls or a validation exception.
• Change approval with unresolved product, process, or supply implications.
• Complaint, field-alert, recall, or market-action escalation decisions.
• Commitments made in an FDA 483 response.

Prioritize cases where facts were contested, alternatives had material consequences, residual risk was accepted, or executive and Quality authority were required. Those decisions are most likely to generate expensive reconstruction later.

Capture the reasoning before it disperses

The best time to preserve the reasoning is when the decision is made. The evidence is assembled, assumptions can still be distinguished from facts, dissent can be recorded accurately, and the accountable person can state why the residual risk is acceptable.

Waiting changes the task. What was once a short act of disciplined synthesis becomes a forensic reconstruction colored by later outcomes. FDA’s data-integrity guidance emphasizes complete, consistent, accurate, attributable, and contemporaneously recorded information; it also states that electronic communications supporting CGMP activities may be subject to inspection.⁸

The executive question is therefore not whether the organization needs more documentation. It is whether the permanent record can carry a consequential decision after the people who made it are no longer available.

Make one decision portable this week

Choose one completed high-risk decision and test whether the record can answer for the organization without the original team. If the rationale lives across disconnected records or in someone’s memory, close that specific gap first—then decide which future decisions should receive the same treatment.